Light-chain Amyloidosis

• CLINICAL_TRIALS trial_result · 2025-12-16
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis [Phase 3]

  A Phase 3 study evaluating birtamimab in Mayo Stage IV AL amyloidosis was terminated, but results have been posted on 2025-12-16.

• CLINICAL_TRIALS trial_result · 2025-06-12
  Clinical Trial Update: A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) [Phase 1, Phase 2]

  A phase 1/2 clinical trial evaluating SAR445514 in relapsed/refractory multiple myeloma and light-chain amyloidosis has been terminated.

• CLINICAL_TRIALS trial_result · 2025-05-25
  Clinical Trial Update: Teclistamab in Previously Treated AL Amyloidosis [Phase 2]

  A Phase 2 clinical trial evaluating teclistamab for previously treated light-chain (AL) amyloidosis is currently recruiting.

• CLINICAL_TRIALS trial_result · 2025-04-16
  Clinical Trial Update: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis [Phase 2]

  A Phase 2 trial update reporting completion of daratumumab monotherapy in previously untreated patients with Stage 3B light chain (AL) amylo…

• CLINICAL_TRIALS trial_result · 2025-01-09
  Clinical Trial Update: DapagliFLOzin in Renal AL Amyloidosis (FLORAL) [Phase 2]

  A Phase 2 trial called FLORAL is evaluating the SGLT2 inhibitor dapagliflozin in light-chain (AL) amyloidosis with renal involvement. The st…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2024-10-28
  Clinical Trial Update: Screening to Improve Survival in AL Amyloidosis

  The clinical trial update reports completion of a screening-based study aimed at improving survival in light-chain (AL) amyloidosis. The stu…

• CLINICAL_TRIALS trial_result · 2024-07-08
  Clinical Trial Update: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

  This completed clinical trial studied how the duration of treatment relates to patient response in real-world cases of multiple myeloma or l…

• CLINICAL_TRIALS trial_result · 2023-01-17
  Clinical Trial Update: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis [Phase 1, Phase 2]

  A clinical trial update for STI-6129 in relapsed or refractory systemic AL amyloidosis (Phase 1/Phase 2) with unknown status.

• CLINICAL_TRIALS trial_result · 2018-08-28
  Clinical Trial Update: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis [Phase 1, Phase 2]

  Phase 1/2 open-label dose-escalation trial of NEOD001 in subjects with light chain (AL) amyloidosis completed.

• CLINICAL_TRIALS trial_result · 2017-10-17
  Clinical Trial Update: A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) [Phase 2]

  This update notes the completion of a Phase 2 trial evaluating epigallocatechin-3-gallate (EGCG) for cardiac involvement in light chain (AL)…

• CLINICAL_TRIALS trial_result · 2011-05-10
  Clinical Trial Update: Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis [Phase 1, Phase 2]

  This clinical trial update reports the completion of a Phase 1/2 study evaluating lenalidomide in combination with melphalan and dexamethaso…

• CLINICAL_TRIALS trial_result · 2010-08-13
  Clinical Trial Update: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis [Phase 1, Phase 2]

  Open-label Phase 1/2 study of VELCADE (bortezomib) for injection in patients with light-chain (AL) amyloidosis has completed, with results p…